Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

Inclusion Criteria

• •Documented T-cell leukemia (precursor T-lymphoblastic leukemia/lymphomia or T-PLL)
• •Failure to have responded to one or more standard regimens for their disease.
• •Performance status of \<=2 by Eastern Cooperative Oncology Group (ECOG) criteria
• •All ages are eligible
• •Life expectancy of at least 3 months
• •Adequate liver function (aspartate transaminase \[AST\] and/or alanine transaminase \[ALT\] not \>3 times upper limits or normal \[ULN\])
• •Adequate kidney function (calculated creatinine clearance \>50 mL/min)
• •Negative urine pregnancy test within 2 to 7 days prior to the start of study treamtment in females of childbearing potential
• •Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study
• •Signed informed consent/assent form (ICF) prior to start of any study specific procedures